SkinHealth Systems (SKIN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
12 Aug, 2026Executive summary
Special Stockholders' Meeting scheduled for September 22, 2026, to address key corporate actions.
Shareholders are encouraged to review proxy materials and vote online or virtually at the meeting.
Voting matters and shareholder proposals
Proposal to approve a reverse stock split of Class A Common Stock at a ratio between 1-for-5 and 1-for-20, with the exact ratio determined by the board.
Proposal to approve adjournment of the meeting if more time is needed to solicit votes or establish a quorum.
Board recommends voting in favor of both proposals.
Board of directors and corporate governance
Board retains sole discretion to set the reverse stock split ratio within the approved range.
Partial view of Summaries dataset, powered by Quartr API
Latest events from SkinHealth Systems
- Shareholders will vote on a reverse stock split to help maintain Nasdaq listing compliance.SKIN
Proxy filing - Q2 2026 sales fell 7.8%, but margins and EBITDA improved amid ongoing market challenges.SKIN
Q2 2026 - Vote sought on a reverse stock split to maintain Nasdaq listing and increase share price.SKIN
Proxy filing - Director elections, auditor ratification, and executive pay were addressed; no questions submitted.SKIN
AGM 2026 - Adjusted EBITDA rose to $8.5M as sales fell and guidance was lowered amid market headwinds.SKIN
Q1 2026 - Virtual annual meeting to vote on directors, auditor, and executive pay, with focus on governance and ESG.SKIN
Proxy filing - Margins and profitability improved in 2025, with stable outlook and growth expected in 2027.SKIN
Q4 2025 - Gross margin rebounded to 51.6% in Q3 2024 despite a 19.1% sales decline.SKIN
Q3 2024 - Net sales dropped 22.9% as device sales lagged, prompting a downward revision to 2024 guidance.SKIN
Q2 2024